Free shipping on all orders over $ 500

CFT7455

Cat. No. M11441
CFT7455  Structure
Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CFT7455 is an orally active inhibitor of zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). CFT7455 is an anticancer agent that binds cereblon E3 ligase with high affinity (Kd 0.9 nM) (WO2022032132A1; Compound 1).

Chemical Information
Molecular Weight 469.54
Formula C28H27N3O4
CAS Number 2504235-67-8
Solubility (25°C) N/A
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Related Ligand for E3 Ligase Products
2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2,6-Bis(benzyloxy)pyridine-3-boronic acid

2,6-Bis(benzyloxy)pyridine-3-boronic acid

2,6-Bis(benzyloxy)-3-bromopyridine

2,6-Bis(benzyloxy)-3-bromopyridine

2,6-bis(benzyloxy)pyridin-3-amine

2,6-bis(benzyloxy)pyridin-3-amine

3-[2,5-Difluoro-4-(4-piperidinyl)phenyl]-2,6-piperidinedione

3-[2,5-Difluoro-4-(4-piperidinyl)phenyl]-2,6-piperidinedione

  Catalog
Abmole Inhibitor Catalog




Keywords: CFT7455 supplier, Ligand for E3 Ligase, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.